BSE · 524590
Hemo Organic Limited
Revenue & net profit by period
Bars = revenue (₹ Cr) · line = net profit (₹ Cr). Straight from disclosed results.
Latest period: revenue ₹2 Cr with net profit ₹0 Cr — a 6.6% net margin, versus -1168.58% the period before.
Shareholding
As of 2026-06-30
- Promoter16.85%
- Public83.15%
4,821 shareholders on record
Promoter holding trend
Each disclosed period, oldest to newest
52-week position
Where the current price sits in its yearly band
The band spans 3.02× from low to high.
Risk flags
Derived from disclosed data
- Under exchange surveillance — GSM · GSM 4. Trading may carry price bands, periodic call auction or higher margins.
Peer comparison
Trading · ranked #454 of 666 by market cap · medians across 50 industry peers
| Company | Mkt cap | P/E | P/B | ROE | Margin |
|---|---|---|---|---|---|
| Adani Enterprises Limited | ₹3,79,897 Cr | 24.35 | 4.76 | 3.42% | 9.3% |
| Avenue Supermarts Limited | ₹2,60,373 Cr | 97.99 | 10.64 | 12.14% | 4.32% |
| Trent Ltd. | ₹1,46,892 Cr | 68.11 | 21.03 | 32.2% | 8.34% |
| FSN E-Commerce Ventures Ltd. | ₹78,254 Cr | — | 54.42 | 13.87% | 1.99% |
| Vishal Mega Mart Limited | ₹55,976 Cr | 76.06 | 7.55 | 11.32% | 6.5% |
| Premier Energies Limited | ₹46,998 Cr | 45.1 | 10.91 | 35.05% | 19.3% |
| Aditya Infotech Limited | ₹39,736 Cr | — | 21.17 | 19.61% | 8.72% |
| Aegis Logistics Limited | ₹33,154 Cr | 42.54 | 5.48 | 14.83% | 10.78% |
| Redington Limited | ₹18,442 Cr | 11.84 | 1.82 | 14.67% | 1.25% |
| Honasa Consumer Limited | ₹13,451 Cr | 103.62 | 9.53 | 14.16% | 8.36% |
| Hemo Organic Limited(this company) | ₹8 Cr | — | 0 | -585.48% | -82.8% |
AI analysis
AI-generated · google/gemini-2.5-flashHemo Organic Limited is listed with a market capitalization of Rs 8 Cr. As of March 2025, the company reported an EPS of 0.47 and a negative Return on Equity (ROE) of -585.48%. The book value per share is -2.7.
Positives
- +The company has a debt-to-equity ratio of 0, indicating no outstanding debt.
- +Promoter pledge is 0%, indicating no shares are pledged by the promoters.
- +Revenue increased significantly from Rs 0.0226 Cr in Mar 2024 to Rs 2.4842 Cr in Mar 2025.
Negatives
- −The company reported a negative Net Profit Margin of -82.8%.
- −Return on Equity (ROE) is significantly negative at -585.48%.
- −Return on Capital Employed (ROCE) is negative at -17.3412%.
- −The company has a negative book value of -2.7.
- −Quarterly results have shown losses in recent periods, with a net profit of -0.07 Cr in June 2026.
- −The company is under GSM 4 surveillance.
Financial Performance
Hemo Organic Limited reported revenue of Rs 2.4842 Cr in March 2025, a significant increase from Rs 0.0226 Cr in March 2024. The net profit was Rs 0.1639 Cr in March 2025, compared to a net loss of Rs -0.2641 Cr in March 2024. The EPS improved from -0.76 in March 2024 to 0.47 in March 2025.
Profitability & Returns
The company's profitability has been volatile. In March 2025, the Net Profit Margin stood at -82.8%. The Return on Equity (ROE) was -585.48% and Return on Capital Employed (ROCE) was -17.3412% in March 2025, indicating persistent challenges in generating returns from equity and capital.
Balance Sheet
Hemo Organic Limited has a negative book value of -2.7. The debt-to-equity ratio is 0, indicating the absence of debt on its books as of the latest available data. There is no dividend yield reported for the company.
Ownership & Pledges
As of June 30, 2026, promoters held 16.8481% of the company's shares. Public shareholding was 83.1519%. There were no shares pledged by the promoters. The number of shareholders increased from 1390 in September 2016 to 4821 in June 2026.
Regulatory & Surveillance
Hemo Organic Limited is under surveillance with a 'GSM' label and specifically subject to 'GSM 4' measures. This indicates heightened scrutiny from regulators regarding the company's financials or operations.
Data as of — price: 2026-07-30 · financials: Mar 25 · shareholding: Jun 26. Figures are restated only when the company files again, so a period shown here is the most recent one on record — not necessarily the current quarter.
How this is produced: every figure above is computed from exchange filings and financial data mirrored by IPO Plus — no figure is generated or estimated. This is a factual summary for information and education only. It is not investment advice, not a recommendation to buy, sell or hold any security, and contains no price targets. Verify against the company's filings and the exchanges before any decision.